- 2,2-Dimethyl-3-(2-methyl-1-propenyl) cyclopropanecarboxylic acid
- 2-Methyl-4-oxo-3-(2,4-pentadienyl)-2-cyclopenten-2,2-dimethyl-3-(2-methyl-1-propenyl)cyclopropane carboxylate
- (+)-Pyrethronyl (+)-trans-Chrysanthematee
Registry Numbers and Inventories.
EC Index Number
Harmful; Dangerous for the Environment
Agricultural Chemical and Pesticide; Natural Product
Swiss Giftliste 1
Boiling point, °C
146 - 148 (0.002 torr)
Vapor pressure, mmHg
2E-5 (25 C)
1.5192 g/cm3 (18 C)
Solubility in water
1.5237 (20 C)
Partition coefficient, pKow
Hazards and Protection.
Keep containers tightly closed in a well ventilated area. Should be refrigerated and stored in darkness.
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Wear appropriate eye protection and protective clothing to prevent skin and eye contact.
Condition: emergency or planned entry into unknown concentrations or idlh conditions. Any self-contained breathing apparatus that has a full facepiece and is operated in a pressure-demand or other positive pressure-mode. Any supplied-air respirator that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode in combination with an auxiliary self-contained breathing apparatus operated in pressure-demand or other positive-pressure mode.
Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.
Oxidizes readily and becomes inactive in air. Pyrethrins are decomposed by exposure to light with loss of insecticidal activity. They are rapidly oxidized and inactivated by air. As the pyrethrins approach 100% purity, their stability decreases; pyrethrin i and ii are less stable than the other compounds. Pyrethrins synergists have a stabilizing effect.
Incompatible with alkalies. Avoid contact with strong oxidizers. Incompatible with lime and ordinary soaps because acids and alkalies speed up processes of hydrolysis.
Use appropriate media to suppress exposure fire. Use foam, carbon dioxide, dry chemicals when oil formulation is burning, due to hydrocarbon solvents involved.
Slightly flammable. Flammable liquid.
IDHL: 5000 mg/m3.
Nausea, vomiting and abdominal pain commonly occur and develop within 10 to 60 minutes following ingestion.
Hypersensitivity reactions characterized by pneumonitis, cough, dyspnea, wheezing, chest pain, and bronchospasm may occur. Rare cases of respiratory failure and cardiopulmonary arrest have been reported.
Irritant and contact dermatitis may develop. Erythema which mimics sunburn has also been noted after prolonged repeated exposure.
There is no specific antidote for pyrethrin poisoning. Treatment is symptomatic and supportive and includes monitoring for the development of hypersensitivity reactions with respiratory distress. Provide adequate airway management when needed. Gastric decontamination is usually not required unless the pyrethrin product is combined with a hydrocarbon. Allergic reaction: mild: antihistamines with or without epinephrine. Severe: oxygen, aggressive airway management, antihistamines, epinephrine (adult: 0.3 To 0.5 Ml of a 1:1000 solution subcutaneously; child: 0.01 Ml/kg; may repeat in 20 to 30 min), corticosteroids, ecg monitoring, and iv fluids.
Move patient to fresh air. Monitor for respiratory distress. If cough or difficulty breathing develops, evaluate for respiratory tract irritation, bronchitis, or pneumonitis. Administer oxygen and assist ventilation as required. Treat bronchospasm with beta2 agonist and corticosteroid aerosols.
Remove contaminated clothing and wash exposed area thoroughly with soap and water. A physician should examine the area if irritation or pain persists. Vitamin e topical application is highly effective in relieving paresthesias.
Irrigate exposed eyes with copious amounts of tepid water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist, the patient should be seen in a health care facility.